Development of an Oral Push-pull Osmotic Pump of Fenofibrate-loaded Mesoporous Silica Nanoparticles

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2015 Mar 19

PMID 25784799

Citations 7

Authors

Zongzhe Zhao

Chao Wu

Ying Zhao

Yanna Hao

Ying Liu

Wenming Zhao

Affiliations

Soon will be listed here.

Abstract

In this study, mesoporous silica nanoparticles (MSNs) were used to prepare an oral push-pull osmotic pump. Fenofibrate, the selected model drug, was firstly loaded into the MSNs, followed by a suspending agent consisting of a drug layer of push-pull osmotic pump. Fenofibrate-loaded MSNs were characterized by scanning electron microscopy (SEM), transmission electron microscopy (TEM), nitrogen adsorption/desorption analysis, differential scanning calorimetry (DSC), powder X-ray diffractometry (PXRD) analysis, and Fourier-transform infrared (FT-IR) spectroscopy. Polyethylene oxide of molecular weight (MW) 100,000 and polyethylene oxide of MW 6,000,000 were selected as the suspending agent and the expanding agent, respectively. Cellulose acetate was used as the semipermeable membrane, along with polyethylene glycol 6,000 to increase the flexibility and control the membrane permeability. The in vitro dissolution studies indicated that the osmotic pump tablet combined with MSNs was able to deliver fenofibrate in an approximately zero-order manner in 24 hours. A pharmacokinetic study showed that, although the maximum plasma concentration of the osmotic pump was lower than that of the reference formulation, the relative bioavailability was increased, indicating that the osmotic pump was more efficient than the reference tablets. Therefore, using MSNs as a carrier for poorly water-soluble drugs is an effective method for preparing osmotic pump tablets.

Citing Articles

Characterization of Drug with Good Glass-Forming Ability Loaded Mesoporous Silica Nanoparticles and Its Impact Toward in vitro and in vivo Studies.

Budiman A, Anastasya G, Handini A, Lestari I, Subra L, Aulifa D Int J Nanomedicine. 2024; 19:2199-2225.

PMID: 38465205 PMC: 10924831. DOI: 10.2147/IJN.S453873.

Features and Facts of a Gastroretentive Drug Delivery System-A Review.

Vinchurkar K, Sainy J, Khan M, Mane S, Mishra D, Dixit P Turk J Pharm Sci. 2022; 19(4):476-487.

PMID: 36047602 PMC: 9438753. DOI: 10.4274/tjps.galenos.2021.44959.

Mesoporous Materials as Elements of Modern Drug Delivery Systems for Anti-Inflammatory Agents: A Review of Recent Achievements.

Moritz M, Geszke-Moritz M Pharmaceutics. 2022; 14(8).

PMID: 35893798 PMC: 9331996. DOI: 10.3390/pharmaceutics14081542.

Preparation and Characterization of Fenofibrate-Loaded PVP Electrospun Microfibrous Sheets.

Sipos E, Csatari T, Kazsoki A, Gergely A, Bitay E, Szabo Z Pharmaceutics. 2020; 12(7).

PMID: 32629988 PMC: 7407498. DOI: 10.3390/pharmaceutics12070612.

Pure paclitaxel nanoparticles: preparation, characterization, and antitumor effect for human liver cancer SMMC-7721 cells.

Wu C, Gao Y, Liu Y, Xu X Int J Nanomedicine. 2018; 13:6189-6198.

PMID: 30349243 PMC: 6188176. DOI: 10.2147/IJN.S169209.

References

Vallet-Regi M, Balas F, Arcos D . Mesoporous materials for drug delivery. Angew Chem Int Ed Engl. 2007; 46(40):7548-58. DOI: 10.1002/anie.200604488. View

Liu L, Xu X . Preparation of bilayer-core osmotic pump tablet by coating the indented core tablet. Int J Pharm. 2007; 352(1-2):225-30. DOI: 10.1016/j.ijpharm.2007.10.047. View

Mertens B, Cahay B, Klinkenberg R, Streel B . An automated method for the simultaneous determination of pravastatin, 3-hydroxy isomeric metabolite, pravalactone and fenofibric acid in human plasma by sensitive liquid chromatography combined with diode array and tandem mass spectrometry detection. J Chromatogr A. 2008; 1189(1-2):493-502. DOI: 10.1016/j.chroma.2008.01.060. View

Kapoor S, Hegde R, Bhattacharyya A . Influence of surface chemistry of mesoporous alumina with wide pore distribution on controlled drug release. J Control Release. 2009; 140(1):34-9. DOI: 10.1016/j.jconrel.2009.07.015. View

Wang F, Hui H, Barnes T, Barnett C, Prestidge C . Oxidized mesoporous silicon microparticles for improved oral delivery of poorly soluble drugs. Mol Pharm. 2009; 7(1):227-36. DOI: 10.1021/mp900221e. View

Zhang L, Chai G, Zeng X, He H, Xu H, Tang X . Preparation of fenofibrate immediate-release tablets involving wet grinding for improved bioavailability. Drug Dev Ind Pharm. 2010; 36(9):1054-63. DOI: 10.3109/03639041003642081. View

Kilpelainen M, Monkare J, Vlasova M, Riikonen J, Lehto V, Salonen J . Nanostructured porous silicon microparticles enable sustained peptide (Melanotan II) delivery. Eur J Pharm Biopharm. 2010; 77(1):20-5. DOI: 10.1016/j.ejpb.2010.10.004. View

Vialpando M, Aerts A, Persoons J, Martens J, Van den Mooter G . Evaluation of ordered mesoporous silica as a carrier for poorly soluble drugs: influence of pressure on the structure and drug release. J Pharm Sci. 2011; 100(8):3411-3420. DOI: 10.1002/jps.22535. View

Pastor E, Matveeva E, Valle-Gallego A, Goycoolea F, Garcia-Fuentes M . Protein delivery based on uncoated and chitosan-coated mesoporous silicon microparticles. Colloids Surf B Biointerfaces. 2011; 88(2):601-9. DOI: 10.1016/j.colsurfb.2011.07.049. View

10.

Tahvanainen M, Rotko T, Makila E, Santos H, Neves D, Laaksonen T . Tablet preformulations of indomethacin-loaded mesoporous silicon microparticles. Int J Pharm. 2011; 422(1-2):125-31. DOI: 10.1016/j.ijpharm.2011.10.040. View

11.

Kiekens F, Eelen S, Verheyden L, Daems T, Martens J, Van den Mooter G . Use of ordered mesoporous silica to enhance the oral bioavailability of ezetimibe in dogs. J Pharm Sci. 2011; 101(3):1136-44. DOI: 10.1002/jps.23016. View

12.

Zhao P, Jiang H, Jiang T, Zhi Z, Wu C, Sun C . Inclusion of celecoxib into fibrous ordered mesoporous carbon for enhanced oral bioavailability and reduced gastric irritancy. Eur J Pharm Sci. 2012; 45(5):639-47. DOI: 10.1016/j.ejps.2012.01.003. View

13.

Zhang Y, Wang J, Bai X, Jiang T, Zhang Q, Wang S . Mesoporous silica nanoparticles for increasing the oral bioavailability and permeation of poorly water soluble drugs. Mol Pharm. 2012; 9(3):505-13. DOI: 10.1021/mp200287c. View

14.

He Q, Ma M, Wei C, Shi J . Mesoporous carbon@silicon-silica nanotheranostics for synchronous delivery of insoluble drugs and luminescence imaging. Biomaterials. 2012; 33(17):4392-402. DOI: 10.1016/j.biomaterials.2012.02.056. View

15.

Hill A, Geissler S, Weigandt M, Mader K . Controlled delivery of nanosuspensions from osmotic pumps: zero order and non-zero order kinetics. J Control Release. 2011; 158(3):403-12. DOI: 10.1016/j.jconrel.2011.12.005. View

16.

Tabasi O, Falamaki C, Khalaj Z . Functionalized mesoporous silicon for targeted-drug-delivery. Colloids Surf B Biointerfaces. 2012; 98:18-25. DOI: 10.1016/j.colsurfb.2012.04.018. View

17.

Fu C, Liu T, Li L, Liu H, Chen D, Tang F . The absorption, distribution, excretion and toxicity of mesoporous silica nanoparticles in mice following different exposure routes. Biomaterials. 2013; 34(10):2565-75. DOI: 10.1016/j.biomaterials.2012.12.043. View

18.

Jia L, Shen J, Li Z, Zhang D, Zhang Q, Liu G . In vitro and in vivo evaluation of paclitaxel-loaded mesoporous silica nanoparticles with three pore sizes. Int J Pharm. 2013; 445(1-2):12-9. DOI: 10.1016/j.ijpharm.2013.01.058. View

19.

Wang X, Li X, Ito A, Sogo Y, Ohno T . Particle-size-dependent toxicity and immunogenic activity of mesoporous silica-based adjuvants for tumor immunotherapy. Acta Biomater. 2013; 9(7):7480-9. DOI: 10.1016/j.actbio.2013.03.031. View

20.

Zhang X, Yi Y, Qi J, Lu Y, Tian Z, Xie Y . Controlled release of cyclosporine A self-nanoemulsifying systems from osmotic pump tablets: near zero-order release and pharmacokinetics in dogs. Int J Pharm. 2013; 452(1-2):233-40. DOI: 10.1016/j.ijpharm.2013.05.014. View